[EPRS] EPIRUS Biopharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 7.33 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.14 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart EPRS

Refresh chart

Description: EPIRUS Biopharmaceuticals, Inc., a commercial-stage biotechnology company, focuses on developing, manufacturing, and commercializing biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a monoclonal antibody against tumor necrosis factor alpha for the treatment of autoimmune diseases. The company has obtained manufacturing and marketing approval in India for BOW015 as a treatment for rheumatoid arthritis. Its pipeline of biosimilar product candidates also includes BOW050, a biosimilar version of Humira (adalimumab) for the treatment of inflammatory diseases; and BOW030, a biosimilar version of Avastin (bevacizumab) to treat various cancers. EPIRUS Biopharmaceuticals, Inc. was formerly known as fourteen22, Inc. and changed its name to EPIRUS Biopharmaceuticals, Inc. in January 2013. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Fundamental Ratios
Shares Outstanding26.18 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.1 Price/Cash Per Share
Price/Free Cash Flow-0.21 ROA-20.08% ROE-24.95% ROI
Current Ratio10.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities48.27 M Cash From Investing Activities Cash From Operating Activities-8.19 M Gross Profit
Net Profit-7.52 M Operating Profit-7.22 M Total Assets91.48 M Total Current Assets63.37 M
Total Current Liabilities6.16 M Total Debt7.3 M Total Liabilities17.86 M Total Revenue30 K
Technical Data
High 52 week3.4 Low 52 week0.09 Last close0.14 Last change0%
RSI54.39 Average true range0.05 Beta0.31 Volume
Simple moving average 20 days-19.48% Simple moving average 50 days-60.31% Simple moving average 200 days
Performance Data
Performance Week0% Performance Month-49.28% Performance Quart-82.12% Performance Half-93.97%
Performance Year-0.8% Performance Year-to-date0% Volatility daily23.77% Volatility weekly53.14%
Volatility monthly108.91% Volatility yearly377.28% Relative Volume0% Average Volume2.75 M
New High New Low

News

2016-07-01 18:10:52 | ETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : July 1, 2016

2016-06-21 12:57:25 | ETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : June 21, 2016

2016-06-10 19:26:14 | ETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : June 10, 2016

2016-06-09 09:42:59 | Most Popular Healthcare Penny Stocks Among Hedge Funds

2016-06-03 07:55:00 | These 7 Stocks Under $10 Are About to Break Out

2016-05-26 11:11:00 | These 5 Stocks Under $10 Are About to Soar Higher

2016-05-19 13:04:25 | EPIRUS BIOPHARMACEUTICALS, INC. Financials

2016-05-18 22:27:57 | ETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : May 19, 2016

2016-05-17 12:40:08 | EPIRUS Biopharmaceuticals, Inc. :EPRS-US: Earnings Analysis: Q1, 2016 By the Numbers

2016-05-09 16:18:18 | EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes

2016-04-04 12:47:45 | Edited Transcript of EPRS earnings conference call or presentation 15-Mar-16 12:00pm GMT

2016-03-15 06:21:26 | Epirus reports 4Q loss

2015-12-02 12:05:31 | Is Epirus Biopharmaceuticals Inc EPRS A Good Stock To Buy?

2015-12-01 08:55:00 | Volatility Creates Opportunity, Insights on Price Data - Research on Delta Apparel, Epirus Biopharmaceuticals, Shiloh Industries, and LifeVantage

2015-11-27 09:29:04 | Should You Avoid Achaogen Inc AKAO?

2015-11-22 15:42:57 | Is Alliance HealthCare Services, Inc. AIQ A Good Stock To Buy?

2015-11-19 12:30:00 | EPRS: Ready to Initiate Global Registration Trial for BOW015…

2015-11-16 06:34:06 | EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 Infliximab Biosimilar

2015-11-16 06:13:35 | Epirus reports 3Q loss

2015-08-07 08:33:55 | Epirus reports 2Q loss

2015-05-12 07:15:38 | Epirus reports 1Q loss

2015-02-09 13:34:20 | Epirus Biopharmaceuticals Inc EPRS: These Two Funds Open New Positions

2014-09-15 16:08:16 | Epirus, Ranbaxy win India approval for arthritis drug copy